Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-02-09
Pitofsky Jason Files Regeneron Pharmaceuticals (REGN) Form 4 - February 09, 2026
Pitofsky Jason traded 3.0K REGN shares worth $2.1M in this Form 4 filing, reported to the SEC on 2026-02-09.
- Insider
- Pitofsky Jason
- Issuer
- Regeneron Pharmaceuticals, Inc. REGN · NASDAQ
- Filed
- Period
- 2026-02-09
- Accession
- 0002009236-26-000001
- Source
- Official filing on sec.gov ↗
Transactions (12)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Pitofsky Jason | 2026-02-09 | Buy | 1.0K | $492.00 | $492.0K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 20 | $775.95 | $15.5K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 521 | $776.43 | $404.5K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 391 | $777.51 | $304.0K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 563 | $778.35 | $438.2K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 205 | $779.56 | $159.8K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 75 | $780.06 | $58.5K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 26 | $781.37 | $20.3K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 37 | $782.67 | $29.0K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 144 | $783.23 | $112.8K | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 1 | $784.66 | $784.66 | Direct |
| Pitofsky Jason | 2026-02-09 | Sell | 53 | $785.72 | $41.6K | Direct |
| Net change | −1.0K | −$1.1M | ||||
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is to address unmet medical needs through innovative treatments derived from its robust pipeline of pharmaceutical products. Regeneron is particularly notable for its contributions to the healthcare industry with products that target ailments such as eye diseases, inflammatory conditions, and cancer. Among its key offerings are EYLEA, an injection for retinal diseases, and Dupixent, used to treat eczema and asthma. Based in Tarrytown, New York, Regeneron employs cutting-edge technologies like its VelociSuite platform, which enhances drug invention capabilities. The company plays a significant role in the biotechnology sector by delivering high-impact therapies that improve patient outcomes. With a strong emphasis on research and development, Regeneron continues to expand its impact across global markets, providing vital solutions to complex health challenges.
Track REGN insider activity
Get alerted when Regeneron Pharmaceuticals, Inc. executives buy or sell their shares.